Company news

Gilead Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

October 30, 2026

Third Quarter 2026 Summary of Remarks

October 29, 2026

Gilead Sciences Announces Third Quarter 2026 Financial Results

October 29, 2026

Canadians Living with Primary Biliary Cholangitis (PBC) One Step Closer to New Treatment Option as Gilead Reaches Milestone National Agreement for LYVDELZI® (seladelpar)

October 27, 2026

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

October 22, 2026

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

October 22, 2026

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

October 19, 2026

Phase 2 SWIFT Study of Emvistegrast, a Potential Differentiated Once-daily Oral Treatment, Meets Primary Endpoint in Ulcerative Colitis

October 19, 2026

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

October 15, 2026

Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

September 17, 2026

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

September 16, 2026

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

September 15, 2026

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

September 8, 2026

Breaks Ground on New Biologics Facility as Part of $32 Billion U.S. R&D and Manufacturing Investment

August 28, 2026

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens

August 27, 2026

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

August 26, 2026

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

August 24, 2026

Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

August 6, 2026

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

August 4, 2026

Statement on California Supreme Court Decision in TDF Litigation

August 3, 2026

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

July 24, 2026

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

July 21, 2026

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

July 21, 2026

Gilead Sciences: Supports the PARTNERS Trial to Advance Research on Potential Treatments for Ebola Virus Disease

July 2, 2026

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

June 23, 2026

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

June 23, 2026

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

June 15, 2026

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

June 12, 2026

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

June 11, 2026

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

June 8, 2026

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

June 5, 2026

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

June 3, 2026

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

June 1, 2026

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)

May 27, 2026

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

May 22, 2026

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

May 22, 2026

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

May 21, 2026

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

May 21, 2026

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

May 21, 2026

Gilead Prices $3 Billion of Senior Unsecured Notes

May 13, 2026

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

May 13, 2026

National casting call for E. Lynn Harris Invisible Life: The Musical With Original Score by Ashford & Simpson Announced

May 11, 2026

Gilead Sciences Announces First Quarter Financial Results

May 7, 2026

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

May 1, 2026

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

April 29, 2026

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

April 28, 2026

AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

April 27, 2026

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

April 21, 2026

Gilead Sciences Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions

April 21, 2026

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

April 17, 2026

Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 47 decks. Every deck is listed under its year.